Two Funds, One Decision
For investors looking to anchor part of their portfolio in consumer staples, two ETFs keep coming up in the same breath: State Street’s XLP and iShares’ IYK. Both track a similar corner of the market, both carry a reputation for low volatility, and both have delivered comparable returns over time. But they are not the same fund, and the differences between them – in cost, composition, and underlying philosophy – are worth pulling apart before committing capital to either one.
The fee gap alone is striking.
XLP charges an annual expense ratio of 0.08%, while IYK comes in at 0.37% – a difference of 0.29 percentage points that compounds quietly but persistently over a holding period of several years. That gap won’t make headlines on any given Tuesday, but across a decade of ownership, it represents a meaningful drag on returns for IYK holders, assuming all else remains equal. Whether all else actually remains equal is the more interesting question.
What You’re Actually Buying
XLP is a straightforward fund. It tracks the Consumer Staples Select Sector Index, which means its holdings are concentrated in the companies most investors picture when they hear “consumer staples” – food and beverage producers, household product companies, supermarket chains, and tobacco. The fund is heavily weighted toward names like Procter and Gamble, Costco, and Coca-Cola. There is no ambiguity about what sector exposure you are getting, which is part of the appeal for investors who want a clean, surgical allocation to staples and nothing else.
IYK operates differently. The iShares U.S. Consumer Staples ETF draws from a broader index and extends its reach into healthcare and materials companies alongside the traditional staples names. That diversification is either a feature or a bug depending on what you’re trying to accomplish. If you already hold a dedicated healthcare ETF and a materials position, IYK’s overlap could muddy your overall allocation in ways that are hard to track. If you’re building a simpler portfolio and want some natural spread across defensive sectors, that same breadth could work in your favor.
The return profiles of the two funds have historically been similar, which makes the composition difference harder to evaluate by looking at performance data alone. When two funds produce comparable results through different means, the divergence in their underlying holdings matters more during market stress – when correlations shift and sector-specific dynamics come to the surface. In a sharp consumer-driven downturn, XLP’s pure-play construction could behave very differently from IYK’s blended exposure, even if their trailing five-year charts look nearly identical today.
The Cost Math at Work
A 0.29% annual fee difference doesn’t sound alarming in isolation. But the arithmetic of compounding fees is relentless. On a $50,000 position held for 10 years, assuming identical gross returns, the investor in IYK would pay roughly $1,450 more in fees than the XLP holder over that period – money that never gets the chance to compound. On $100,000, that figure doubles. These are not catastrophic losses, but they are entirely avoidable ones, and in a category like consumer staples where the expected annual returns are modest by design, giving up a quarter of a percentage point per year to fees is a more significant sacrifice than it would be in a high-growth equity category.
There is a reasonable counter-argument. If IYK’s broader sector exposure – its healthcare and materials tilt – produces even marginally better risk-adjusted returns than XLP in certain market environments, the fee premium could pay for itself. That is a legitimate possibility, not a guarantee. Investors betting on IYK to outperform net of fees are essentially betting that its diversification will consistently add more value than the 0.29% it costs them each year. Over long holding periods, that is a difficult bar to clear.
State Street built its reputation in part on cost-efficient index products, and XLP at 0.08% reflects that institutional discipline. IYK, at 0.37%, is not expensive by any absolute measure – plenty of actively managed funds charge ten times that – but in the passive ETF space, where basis points are the primary battleground, 0.37% is on the higher end for a fund competing in the same general category. For investors who have spent time thinking about fee minimization – and the compounding math is a strong argument that they should – XLP starts with a structural advantage that IYK has to work hard to overcome.
For those comparing how fees stack up against return potential in other ETF matchups, this breakdown of cost versus small-cap returns covers similar ground from a different angle.
The Decision Is a Portfolio Question
Framing this as a simple “better value” question misses the actual choice investors face. Neither fund is mispriced or poorly constructed – they are just built for different portfolio roles. XLP is the more disciplined, lower-cost option for an investor who wants pure consumer staples exposure and already manages healthcare and materials through separate positions. IYK makes more sense as a single-ticket defensive allocation for someone who wants a little more breadth inside one fund and is willing to pay for it.
The low volatility profile that both funds share is a meaningful draw for investors who use consumer staples as a ballast position – something to dampen portfolio swings during equity market downturns without abandoning equities entirely. In that context, the choice between XLP and IYK is less about which one will win on returns and more about which one fits the surrounding portfolio architecture without creating unintended overlaps or gaps.
What neither fund can offer is clarity about which defensive sectors will hold up best in the next downturn. IYK’s healthcare exposure might provide a cushion if a slowdown hits consumer spending hard but spares medical demand. XLP’s concentrated staples focus might outperform if healthcare names get caught in a regulatory or pricing headwind. Both scenarios are plausible, neither is predictable, and the 0.29% fee sitting between them isn’t going anywhere regardless of which one plays out.
